GlassScriptPhysician profile
Sandra Amaral
NPI 1700824877
$14,223.16
in general payments reported to CMS, 2019-2025
7 companies · $4,500 in 2025
The $4,500 reported for 2025 was more than what 86% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,490 · 2020: $1,460 · 2021: $838 · 2022: $1,513 · 2023: $2,475 · 2024: $948 · 2025: $4,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,638 · Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,637.50 |
| Food and Beverage | $285.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,500.00 | 2021-2024 | Nulojix |
| Horizon Therapeutics Plc | $3,950.00 | 2019-2020 | |
| Novo Nordisk INC | $1,913.35 | 2025 | Rivfloza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,760.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $902.31 | 2021-2025 | Ultomiris |
| Novo Nordisk Health Care Ag | $122.83 | 2024 | |
| Apellis Pharmaceuticals, INC. | $74.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Amaral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.